Search clinical trials for: Gardasil and Gardasil-9

Total 875 results

Boston Medical Center
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study

Human Papilloma Virus

United States
Laval University
Centers for Disease Control and Prevention

Completed

Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9

Human Papillomavirus Vaccines

Canada
Western Institute for Veterans Research
Merck Sharp & Dohme LLC; University of Utah

Recruiting

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Warts

United States
Eastern Virginia Medical School
Merck Sharp & Dohme LLC

Recruiting

Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination

Papillomavirus Vaccines

United States
Boston Medical Center
Merck Sharp & Dohme LLC

Recruiting

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

HPV Infection

United States
London School of Hygiene and Tropical Medicine
Merck Sharp & Dohme LLC; Public Health England; University of Cambridge

Active, not recruiting

HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial (HPV)

Human Papillomavirus Vaccine

Gambia
National Institute of Allergy and Infectious Diseases...

Recruiting

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Idiopathic CD4 T Cell Lymphocytopenia

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Cervical Cancer | Papillomavirus Infections | CIN | Genital Wart | VIN

China
Centre Hospitalier Universitaire de la Réunion

Completed

Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students (PROM SSCOL)

Papilloma Viral Infection

France
Eastern Virginia Medical School
Merck Sharp & Dohme LLC

Unknown

A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study

Genital Human Papilloma Virus Infection

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Not yet recruiting

HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL

Anal Cancer | Human Papilloma Virus | Anal Intraepithelial Neoplasia

Canada
Milton S. Hershey Medical Center

Withdrawn

HPV Vaccine in Postpartum Women

HPV Infection
Louisiana State University Health Sciences Center...
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV (AGO-Gard)

Cervical Intraepithelial Neoplasia | Human Immunodeficiency Virus | Anal Intraepithelial Neoplasia | Papillomavirus Infection | Papillomavirus Vaccines | Serology | Oral Cavity Infection

United States
Laval University

Completed

Immunogenicity and Safety of Gardasil-9 and Cervarix

HPV Vaccines Immunogenicity and Safety

Canada
Medical College of Wisconsin
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of HPV Vaccine in Transplant Recipients.

Chronic Kidney Diseases | Kidney Transplant

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Uterine Cervical Neoplasms | Papillomavirus Infections | Vulvar Neoplasms | Vaginal Neoplasms | Condylomata Acuminata | Adenocarcinoma in Situ

Vietnam
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Papillomavirus Infections

Japan
Merck Sharp & Dohme LLC

Active, not recruiting

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Genital Warts

China
Miquel Angel Pavon Ribas
Catalan Institute of Health; Hospital del Mar

Recruiting

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) (RIFT-HPV)

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Human Papillomavirus (HPV) Infections | High-risk HPV | HPV-16/ 18

Spain
Massachusetts General Hospital
Bill and Melinda Gates Foundation; Kenya Medical Research Institute

Active, not recruiting

The KEN SHE Study on HPV-vaccine Efficacy

Papillomavirus Infections

Kenya
Kenya Medical Research Institute
Merck Sharp & Dohme LLC; University of Washington

Completed

A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years

HIV-1 Infection | Human Papillomavirus
Imperial College London

Not yet recruiting

Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial (NOVEL)

Neoplasia
Erasmus Medical Center
Dutch Cancer Society

Not yet recruiting

Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL (VulVaccin)

HPV | Vulvar HSIL

Netherlands
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Vaccines | Meningococcal Vaccines

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Preparedness Study - HPV Vaccine

Sexual Transmission of Infection

United States, South Africa
Universitaire Ziekenhuizen KU Leuven

Completed

Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

Hiv | Human Papilloma Virus | Organ Transplants

Belgium
Tuen Mun Hospital

Completed

Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study

Systemic Lupus Erythematosus

China
Preventive Oncology International, Inc.
Merck Sharp & Dohme LLC; Peru Instituto Nacional de Enfermadades Neoplasticas...

Completed

The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru (PERCAPS)

Cervical Cancer | Cervical Intraepithelial Neoplasia | Human Papillomavirus | Cervical Dysplasia | Cervical Neoplasm

Peru
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Gardasil Vaccination in Post Stem Cell Transplant Patients

Stem Cell Transplant | Immunogenicity | Gardasil Vaccine

United States
Sarah Hostetter, MD

Completed

Gardasil Knowledge

HPV

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Papillomavirus Infections

United States, Belgium, Brazil, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Spain, Taiwan, Thailand
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Not yet recruiting

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

Cervical Cancer | Condylomata Acuminata

China
Sinocelltech Ltd.

Recruiting

A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Randomized | Prevention | Interventional

China
PharmaJet, Inc.
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

Vaccine Reaction

Indonesia
University of British Columbia
Merck Canada Inc.

Completed

Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine (Merck08)

Human Papillomavirus

Canada
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

Cervical Cancer | Condylomata Acuminata

China
Partha Basu
All India Institute of Medical Sciences, New Delhi; Tata Memorial Centre; Deutsches... and other collaborators

Active, not recruiting

Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

Cervical Cancer | Cervical Precancerous Lesions

India
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)

Warts, Genital | Neoplasms, Anal

Japan
University of Fukui
Merck Sharp & Dohme LLC

Unknown

The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years

Vaccinia | Cancer of Cervix
Wayne State University
Merck Sharp & Dohme LLC

Completed

Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients (GARDASIL)

Systemic Lupus Erythematosus

United States
University of Chicago
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women

Systemic Lupus Erythematosus

United States
Columbia University
Merck Sharp & Dohme LLC; Jhpiego

Active, not recruiting

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Hiv | HPV Infection | HPV Vaccine

Swaziland
Boston Children's Hospital
Merck Sharp & Dohme LLC; Harvard School of Public Health (HSPH)

Completed

Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy (HPV)

Inflammatory Bowel Disease

United States
Merck Sharp & Dohme LLC

Completed

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Cervical Cancer | Genital Warts
Merck Sharp & Dohme LLC

Active, not recruiting

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
National Cancer Institute (NCI)

Completed

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

Adolescent | Human Immunodeficiency Virus | Papillomavirus Vaccines | Human Papillomavirus- 6, 11, 16, 18

United States
Public Health England

Completed

Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls (HPV CSP01)

HPV Infections

United Kingdom
University of Alabama at Birmingham
Merck Investigator Studies Program

Not yet recruiting

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

Human Papilloma Virus

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)

Papillomavirus Infections

China
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Cervical Intraepithelial Neoplasia

United States

Search clinical trials for: Gardasil and Gardasil-9

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations